Molecular modelling of subtypes (α2A, α2B and α2C) of α2-adrenoceptors: A comparative study

Balázs Balogh, András Szilágyi, K. Gyires, David B. Bylund, P. Mátyus

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The therapeutic usefulness of current agents that activate the three α2-adrenoceptors, α2A, α2B and α2C is limited by their lack of subtype selectivity. One approach to the development of subtype-selective agents is the in silico docking of potential ligands to the receptors in quantitative molecular modeling studies. Because the crystal structure of the α2-adrenoceptors is not known, we used homology modeling based on the published structure of bovine rhodopsin. We developed individual models for each of the three receptors, which were found to accurately represent published data from both radioligand binding mutagenesis experiments. Using 18 non-subtype-selective agents to validate the models, the calculated transformed and the experimental binding free energies were satisfactory correlated (r2A = 0.888, r2B = 0.887, r2C = 0.790). The binding pockets differed in size (482-619 Å3) with the α2B receptor subtype having the largest and the α2c the smallest cavity. The binding sites for all three subtypes were found to be essentially identical with the exception of two subtype-specific residues, and thus we were unable to identify any significant differences in the interactions of ligands with the three receptor subtypes. Although, the binding properties of all three receptors are very similar, the differences in pocket volume and two subtype-specific residues in the binding pocket might play an as yet undocumented role in subtype selectivity.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalNeurochemistry International
Volume55
Issue number6
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Adrenergic Receptors
Ligands
Rhodopsin
Mutagenesis
Computer Simulation
Binding Sites
Therapeutics

Keywords

  • α-Adrenoceptor
  • AutoDock
  • Binding free energy
  • Docking
  • Homology modelling
  • Subtype selectivity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Molecular modelling of subtypes (α2A, α2B and α2C) of α2-adrenoceptors : A comparative study. / Balogh, Balázs; Szilágyi, András; Gyires, K.; Bylund, David B.; Mátyus, P.

In: Neurochemistry International, Vol. 55, No. 6, 11.2009, p. 355-361.

Research output: Contribution to journalArticle

Balogh, Balázs ; Szilágyi, András ; Gyires, K. ; Bylund, David B. ; Mátyus, P. / Molecular modelling of subtypes (α2A, α2B and α2C) of α2-adrenoceptors : A comparative study. In: Neurochemistry International. 2009 ; Vol. 55, No. 6. pp. 355-361.
@article{7e5d6e79d7724c67a75f37fa991bc8d9,
title = "Molecular modelling of subtypes (α2A, α2B and α2C) of α2-adrenoceptors: A comparative study",
abstract = "The therapeutic usefulness of current agents that activate the three α2-adrenoceptors, α2A, α2B and α2C is limited by their lack of subtype selectivity. One approach to the development of subtype-selective agents is the in silico docking of potential ligands to the receptors in quantitative molecular modeling studies. Because the crystal structure of the α2-adrenoceptors is not known, we used homology modeling based on the published structure of bovine rhodopsin. We developed individual models for each of the three receptors, which were found to accurately represent published data from both radioligand binding mutagenesis experiments. Using 18 non-subtype-selective agents to validate the models, the calculated transformed and the experimental binding free energies were satisfactory correlated (r2A = 0.888, r2B = 0.887, r2C = 0.790). The binding pockets differed in size (482-619 {\AA}3) with the α2B receptor subtype having the largest and the α2c the smallest cavity. The binding sites for all three subtypes were found to be essentially identical with the exception of two subtype-specific residues, and thus we were unable to identify any significant differences in the interactions of ligands with the three receptor subtypes. Although, the binding properties of all three receptors are very similar, the differences in pocket volume and two subtype-specific residues in the binding pocket might play an as yet undocumented role in subtype selectivity.",
keywords = "α-Adrenoceptor, AutoDock, Binding free energy, Docking, Homology modelling, Subtype selectivity",
author = "Bal{\'a}zs Balogh and Andr{\'a}s Szil{\'a}gyi and K. Gyires and Bylund, {David B.} and P. M{\'a}tyus",
year = "2009",
month = "11",
doi = "10.1016/j.neuint.2009.05.004",
language = "English",
volume = "55",
pages = "355--361",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Molecular modelling of subtypes (α2A, α2B and α2C) of α2-adrenoceptors

T2 - A comparative study

AU - Balogh, Balázs

AU - Szilágyi, András

AU - Gyires, K.

AU - Bylund, David B.

AU - Mátyus, P.

PY - 2009/11

Y1 - 2009/11

N2 - The therapeutic usefulness of current agents that activate the three α2-adrenoceptors, α2A, α2B and α2C is limited by their lack of subtype selectivity. One approach to the development of subtype-selective agents is the in silico docking of potential ligands to the receptors in quantitative molecular modeling studies. Because the crystal structure of the α2-adrenoceptors is not known, we used homology modeling based on the published structure of bovine rhodopsin. We developed individual models for each of the three receptors, which were found to accurately represent published data from both radioligand binding mutagenesis experiments. Using 18 non-subtype-selective agents to validate the models, the calculated transformed and the experimental binding free energies were satisfactory correlated (r2A = 0.888, r2B = 0.887, r2C = 0.790). The binding pockets differed in size (482-619 Å3) with the α2B receptor subtype having the largest and the α2c the smallest cavity. The binding sites for all three subtypes were found to be essentially identical with the exception of two subtype-specific residues, and thus we were unable to identify any significant differences in the interactions of ligands with the three receptor subtypes. Although, the binding properties of all three receptors are very similar, the differences in pocket volume and two subtype-specific residues in the binding pocket might play an as yet undocumented role in subtype selectivity.

AB - The therapeutic usefulness of current agents that activate the three α2-adrenoceptors, α2A, α2B and α2C is limited by their lack of subtype selectivity. One approach to the development of subtype-selective agents is the in silico docking of potential ligands to the receptors in quantitative molecular modeling studies. Because the crystal structure of the α2-adrenoceptors is not known, we used homology modeling based on the published structure of bovine rhodopsin. We developed individual models for each of the three receptors, which were found to accurately represent published data from both radioligand binding mutagenesis experiments. Using 18 non-subtype-selective agents to validate the models, the calculated transformed and the experimental binding free energies were satisfactory correlated (r2A = 0.888, r2B = 0.887, r2C = 0.790). The binding pockets differed in size (482-619 Å3) with the α2B receptor subtype having the largest and the α2c the smallest cavity. The binding sites for all three subtypes were found to be essentially identical with the exception of two subtype-specific residues, and thus we were unable to identify any significant differences in the interactions of ligands with the three receptor subtypes. Although, the binding properties of all three receptors are very similar, the differences in pocket volume and two subtype-specific residues in the binding pocket might play an as yet undocumented role in subtype selectivity.

KW - α-Adrenoceptor

KW - AutoDock

KW - Binding free energy

KW - Docking

KW - Homology modelling

KW - Subtype selectivity

UR - http://www.scopus.com/inward/record.url?scp=67650096635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650096635&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2009.05.004

DO - 10.1016/j.neuint.2009.05.004

M3 - Article

C2 - 19447153

AN - SCOPUS:67650096635

VL - 55

SP - 355

EP - 361

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 6

ER -